



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of:	§	
James B. Camden	§	Group Art Unit: 1614
James C. Quada, Jr.	§	
Joseph K. Agyin	§	
	§	
Serial No. 10/634,542	§	
	§	Examiner: Clinton T. Ostrup
Filed: August 5, 2003	§	
	§	
For: Compounds and Methods for Use	§	
Thereof in the Treatment of	§	
Viral Infections	§	

**POWER OF ATTORNEY;
STATEMENT UNDER 37 CFR 3.73(b)**

As the undersigned representative of the Assignee of the entire right, title and interest of the above cited patent, UAF Technologies and Research, LLC, an Arizona nonprofit corporation, I hereby appoint practitioners associated with the Customer Number: **27683**. The correspondence address for the above-identified patent is associated with Customer Number **27683** and does not change.

The Assignee of the above-cited patent application is UAF Technologies and Research, LLC by virtue of a chain of title from the inventors of the above-identified patent application to earliest priority application USSN 09/670,166 (then Attorney Docket No: 8253) to UAF Technologies and Research, LLC as shown by the following documents:

- Assignment from James B. Camden to The Procter & Gamble Company dated July 31, 2001;
- Assignment from James C. Quada, Jr. and Joesph K. Agyin to CTRC Research Foundation dated August 21, 2001 and August 20, 2001, respectively;
- Assignment from CTRC Research Foundation to The Procter & Gamble Company dated August 21, 2001;
- Assignment from The Procter & Gamble Company to the University of Arizona Foundation dated October 24, 2002 (Reel/Frame 013447/0227); and
- Assignment from the University of Arizona Foundation to UAF Technologies and Research, LLC dated October 6, 2003 (Reel/Frame 014051/0993).

A copy of each of the above-listed assignments and corresponding recordation documents (for the latter two) in the chain of title is attached hereto.

The undersigned hereby declares that all statements made herein of the undersigned's own knowledge are true; and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

UAF Technologies and Research, LLC

September 27, 2004
Date

Alfred "Bo" Statham
Alfred "Bo" Statham
Manager
(702) 632-4106

Attachments: Assignments cited herein